Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors Alentis raises $181.4M series D financing to advance Claudin-1 ADCs for solid tumors Alentis Family Event 2023 impression Alentis Therapeutics presents ALE.F02 data for organ fibrosis at the European Respiratory Society International Congress ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1 ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY
